Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11256315 | 0.87 | NPSR1 (0.39) | HDAC8APOBEC3AAPOBEC3GNPSR1KDM4E | |
| Trifluoromethanesulfonic Acid SCHEMBL4476327 | 0.85 | GPR3 (0.42) | ACHE | |
| SCHEMBL29502455 | 0.85 | — | — | |
| SCHEMBL300758 | 0.85 | — | — | |
| SCHEMBL717113 | 0.83 | LMNA (0.49) | KDM4ELMNAHTTSMN1; SMN2 | |
| SCHEMBL31753460 | 0.83 | LMNA (0.49) | KDM4ELMNAHTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7950735 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL467422 | 0.83 | — | — | |
| Methane SCHEMBL15323400 | 0.83 | — | — | |
| Iodide SCHEMBL21810784 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108456198-B | Preparation method of vilazodone or hydrochloride thereof | 江苏豪森药业集团有限公司 | 2021-11-26 | — | — | CN | disclosed |
| US-20210251986-A1 | POLYMORPHIC FORMS OF 1-[4-(5-CYANOINDOL-3-YL)BUTYL]-4-(2-CARBAMOYLBENZOFURAN-5-YL) PIPERAZINE HYDROCHLORIDE | MERCK PATENTGESELLSCHAFT (DE) | 2021-08-19 | — | — | US | disclosed |
| US-20190343831-A1 | POLYMORPHIC FORMS OF 1-[4-(5-CYANOINDOL-3-YL)BUTYL]-4-(2-CARBAMOYLBENZOFURAN-5-YL) PIPERAZINE HYDROCHLORIDE | MERCK PATENTGESELLSCHAFT (DE) | 2019-11-14 | — | — | US | disclosed |
| US-9969721-B2 | Process for the preparation of vilazodone hydrochloride and its amorphous form | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2018-05-15 | — | — | US | disclosed |
| US-20180002305-A1 | PROCESS FOR PREPARING BENZOFURAN-2-CARBOXAMIDE DERIVATIVES | SYMED LABS LIMITED (IN) | 2018-01-04 | — | — | US | disclosed |
| US-9796695-B2 | Process for preparing benzofuran-2-carboxamide derivatives | SYMED LABS LIMITED (IN) | 2017-10-24 | — | — | US | disclosed |
| US-20170267655-A1 | PROCESS FOR PREPARING BENZOFURAN-2-CARBOXAMIDE DERIVATIVES | SYMED LABS LIMITED (IN) | 2017-09-21 | — | — | US | disclosed |
| US-20170182037-A1 | POLYMORPHIC FORMS OF 1-[4-(5-CYANOINDOL-3-YL)BUTYL]-4-(2-CARBAMOYLBENZOFURAN-5-YL) PIPERAZINE HYDROCHLORIDE | MERCK PATENTGESELLSCHAFT (DE) | 2017-06-29 | — | — | US | disclosed |
| US-9682946-B2 | Process for preparing benzofuran-2-carboxamide derivatives | SYMED LABS LIMITED (IN) | 2017-06-20 | — | — | US | disclosed |
| US-9624204-B2 | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride | MERCK PATENTGESELLSCHAFT (DE) | 2017-04-18 | — | — | US | disclosed |
| EP-1397357-A2 | POLYMORPHIC FORMS OF 1-'4-(5-CYANOINDOL-3-YL)BUTYL-4-(2-CARBAMOYLBENZOFURAN-5-YL)PIPERAZINE HYDROCHLORIDE | MERCK PATENT GmbH (DE) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002102794-A2 | POLYMORPHIC FORMS OF 1-'4-(5-CYANOINDOL-3-YL)BUTYL-4-(2-CARBAMOYLBENZOFURAN-5-YL)PIPERAZINE HYDROCHLORIDE | MERCK PATENT GMBH (DE) | 2002-12-27 | — | — | WO | disclosed |
| EP-0683166-B1 | 3-Indolylpiperidines | MERCK PATENT GMBH (DE) | 1998-10-28 | — | — | EP | disclosed |
| US-5693655-A | 3-indolylpiperidines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1997-12-02 | — | — | US | disclosed |
| US-5670511-A | Indolepiperidine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1997-09-23 | — | — | US | disclosed |
| EP-0648767-B1 | Piperdine and piperazine derivatives which affect the C.N.S. | MERCK PATENT GMBH (DE) | 1997-05-28 | — | — | EP | disclosed |
| EP-0722942-A1 | Indole piperidine derivatives | MERCK PATENT GmbH (DE) | 1996-07-24 | — | — | EP | disclosed |
| US-5532241-A | Piperidines and piperazines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1996-07-02 | — | — | US | disclosed |
| EP-0683166-A1 | 3-Indolylpiperidines | MERCK PATENT GmbH (DE) | 1995-11-22 | — | — | EP | disclosed |
| EP-0648767-A1 | Piperdine and piperazine derivatives which affect the C.N.S. | MERCK PATENT GmbH (DE) | 1995-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002305-A1 | PROCESS FOR PREPARING BENZOFURAN-2-CARBOXAMIDE DERIVATIVES | HTR3C, VIL1, HTR4 | HDAC8 226/4885APOBEC3A 812/4885APOBEC3G 1408/4885 |
| US-20170267655-A1 | PROCESS FOR PREPARING BENZOFURAN-2-CARBOXAMIDE DERIVATIVES | HTR3C, VIL1, HTR4 | HDAC8 226/4885APOBEC3A 812/4885APOBEC3G 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.